- OXB has signed a new Commercial Supply Agreement with Bristol Myers Squibb to manufacture and supply lentiviral vectors for CAR-T programs.
- Commercial manufacturing is expected to begin in 2026 at OXB facilities in the UK and the US, subject to regulatory approval.
OXB said it has expanded its strategic partnership with Bristol Myers Squibb through a new Commercial Supply Agreement covering the manufacture and supply of lentiviral vectors for CAR-T programs. The agreement builds on an existing relationship between the companies that was first announced in March 2020.
Under the agreement, OXB expects to commence commercial manufacturing in 2026, subject to regulatory approval of the relevant CAR-T products. Manufacturing will be carried out at OXB’s facilities in Oxford, UK, and Durham, North Carolina, supporting both European and US supply.
OXB said the Commercial Supply Agreement is expected to generate multi-year revenue and supports its existing medium-term financial guidance. The company said the deal reflects continued execution of its focused cell and gene therapy CDMO strategy and expands its contract manufacturing activities into commercial supply.
“The transition from clinical to commercial manufacturing with BMS marks an important milestone for both companies. Having supported these potentially life-saving CAR-T programmes through development, we are confident in their commercial success and look forward to continuing our partnership with BMS.”
Dr. Sebastien Ribault, Chief Business Officer of OXB
The agreement further extends OXB’s role as a manufacturing partner for CAR-T therapies as programs move from clinical development toward commercial production, while Bristol Myers Squibb secures additional lentiviral vector supply capacity for its cell therapy portfolio.
